VEGFA and hepatocellular carcinoma: They observed an increase in the serum concentrations of vascular endothelial growth factor (VEGF) and angiopoietin-2, growth factors responsible for vascular remodeling in tumors, during DAA treatment and this increase correlated with a higher risk of HCC relapse and de novo occurrence [17,18].